Gilead Sciences and Arcus Biosciences Complete Closing of Their 10-Year Partnership to Co-Develop and Co-Commercialize Next-Generation Cancer Immunotherapies
July 16, 2020
Tags:
Under the terms of the agreements, the closing of this transaction triggered a payment of $175 million by Gilead to Arcus.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
.svg)
